Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DARVY LEE MANN

Allopathic & Osteopathic Physicians Pediatrics

NPI
1275832479
CMS profile
1169194
Location
LONGVIEW, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$150.59

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $150.59 23

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DARVY LEE MANN

NPI 1275832479 · CMS profile ID 1169194

Allopathic & Osteopathic Physicians / Pediatrics

LONGVIEW, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275832479?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275832479?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275832479?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1275832479?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $150.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $2.2112/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792679 CMS
PFIZER INC. $2.0811/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792611 CMS
Tris Pharma Inc $15.8510/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701606313 CMS
PFIZER INC. $2.3210/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792613 CMS
PFIZER INC. $2.0809/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792677 CMS
PFIZER INC. $2.0809/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792675 CMS
Ironshore Pharmaceuticals Inc. $16.2109/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707548387 CMS
PFIZER INC. $2.0008/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792649 CMS
Cumberland Pharmaceuticals, Inc. $11.0107/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699733155 CMS
PFIZER INC. $2.0407/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792647 CMS
PFIZER INC. $2.0406/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792645 CMS
Merck Sharp & Dohme Corporation $15.9206/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695586683 CMS
PFIZER INC. $2.5305/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792643 CMS
GlaxoSmithKline, LLC. $18.7805/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670393595 CMS
PFIZER INC. $1.4505/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792639 CMS
Merck Sharp & Dohme Corporation $13.3205/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695487117 CMS
PFIZER INC. $1.9605/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792641 CMS
PFIZER INC. $2.2503/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792609 CMS
Merck Sharp & Dohme Corporation $6.2503/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695383736 CMS
Cumberland Pharmaceuticals, Inc. $12.1602/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699733087 CMS
GlaxoSmithKline, LLC. $12.0402/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670763877 CMS
PFIZER INC. $2.1701/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792607 CMS
PFIZER INC. $1.8401/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673792605 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $150.59 23
PY2020 $67.15 9
PY2021 $149.63 9
PY2022 $300.49 20
PY2023 $408.04 19
PY2024 $226.96 14
PY2025 $385.36 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,716.71 24
PY2024 Principal investigator $61,020.88 14
PY2023 Principal investigator $72,104.63 22
PY2022 Principal investigator $325,094.46 64
PY2021 Principal investigator $289,713.17 73
PY2020 Principal investigator $296,305.70 95
PY2019 Principal investigator $139,835.21 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $155.26 12/31/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 914594559
Principal investigator 1 Merck Sharp & Dohme LLC $18,555.27 12/31/2022 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940400573
Principal investigator 1 Merck Sharp & Dohme LLC $212.88 12/31/2022 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940400575
Principal investigator 1 Merck Sharp & Dohme LLC $938.04 12/31/2022 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940400577
Principal investigator 1 PFIZER INC. $4,454.13 12/30/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949775821
Principal investigator 1 SANOFI PASTEUR INC. $1,318.00 12/21/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568607
Principal investigator 1 SANOFI PASTEUR INC. $1,318.00 12/14/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568603
Principal investigator 1 Merck Sharp & Dohme LLC $22,142.20 12/12/2022 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940400571
Principal investigator 1 PFIZER INC. $3,706.50 12/06/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949775635
Principal investigator 1 GlaxoSmithKline, LLC. $3,413.72 12/02/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 965505343
Principal investigator 1 AstraZeneca UK Limited $3,213.40 11/11/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 914596463
Principal investigator 1 PFIZER INC. $650.22 11/05/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949782303
Principal investigator 1 GlaxoSmithKline, LLC. $9,949.33 11/04/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 965505277
Principal investigator 1 PFIZER INC. $5,007.10 10/25/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949794649
Principal investigator 1 PFIZER INC. $1,500.00 10/22/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949794647
Principal investigator 1 GlaxoSmithKline, LLC. $3,319.46 10/05/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933013
Principal investigator 1 SANOFI PASTEUR INC. $1,050.00 09/28/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568597
Principal investigator 1 GlaxoSmithKline, LLC. $7,274.52 09/23/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943932995
Principal investigator 1 PFIZER INC. $2,807.18 09/22/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949792779
Principal investigator 1 GlaxoSmithKline, LLC. $11,622.59 09/02/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933023
Principal investigator 1 PFIZER INC. $4,356.88 09/02/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949792829
Principal investigator 1 GlaxoSmithKline, LLC. $3,415.62 08/22/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933003
Principal investigator 1 SANOFI PASTEUR INC. $2,636.00 08/12/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568591
Principal investigator 1 PFIZER INC. $4,129.10 08/05/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949803603
Principal investigator 1 PFIZER INC. $644.80 08/05/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949803975
Principal investigator 1 GlaxoSmithKline, LLC. $9,921.78 08/01/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943932997
Principal investigator 1 SANOFI PASTEUR INC. $1,318.00 07/18/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568585
Principal investigator 1 GlaxoSmithKline, LLC. $14,403.72 07/06/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933011
Principal investigator 1 SANOFI PASTEUR INC. $1,318.00 06/29/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568573
Principal investigator 1 GlaxoSmithKline, LLC. $2,234.14 06/24/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933009
Principal investigator 1 PFIZER INC. $751.01 06/24/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949811167
Principal investigator 1 PFIZER INC. $644.80 06/22/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949812315
Principal investigator 1 SANOFI PASTEUR INC. $1,318.00 06/08/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568579
Principal investigator 1 PFIZER INC. $4,703.34 06/07/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949810969
Principal investigator 1 GlaxoSmithKline, LLC. $4,857.38 06/03/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933015
Principal investigator 1 PFIZER INC. $644.80 06/03/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949810971
Principal investigator 1 PFIZER INC. $10,405.46 05/21/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949753431
Principal investigator 1 SANOFI PASTEUR INC. $350.00 05/16/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568569
Principal investigator 1 PFIZER INC. $844.80 05/06/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949753427
Principal investigator 1 GlaxoSmithKline, LLC. $8,402.40 05/04/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933007
Principal investigator 1 SANOFI PASTEUR INC. $4,119.00 04/29/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568563
Principal investigator 1 PFIZER INC. $6,764.23 04/22/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949816895
Principal investigator 1 PFIZER INC. $644.80 04/22/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949816931
Principal investigator 1 PFIZER INC. $1,289.60 04/08/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949816929
Principal investigator 1 PFIZER INC. $11,119.85 04/08/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949817689
Principal investigator 1 GlaxoSmithKline, LLC. $2,806.64 04/06/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943932999
Principal investigator 1 GlaxoSmithKline, LLC. $9,482.21 03/25/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933027
Principal investigator 1 PFIZER INC. $768.95 03/23/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949827385
Principal investigator 1 PFIZER INC. $1,401.27 03/16/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949827383
Principal investigator 1 SANOFI PASTEUR INC. $2,636.00 03/09/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568557
Principal investigator 1 GlaxoSmithKline, LLC. $10,657.34 03/04/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933005
Principal investigator 1 PFIZER INC. $1,735.24 03/04/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949827507
Principal investigator 1 PFIZER INC. $17,584.85 03/04/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949827569
Principal investigator 1 SANOFI PASTEUR INC. $2,239.00 03/04/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568553
Principal investigator 1 PFIZER INC. $350.00 03/03/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949827509
Principal investigator 1 SANOFI PASTEUR INC. $7,169.00 02/25/2022 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 935568547
Principal investigator 1 PFIZER INC. $768.95 02/05/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949828329
Principal investigator 1 GlaxoSmithKline, LLC. $3,841.40 02/02/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933019
Principal investigator 1 GlaxoSmithKline, LLC. $10,336.82 01/26/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933001
Principal investigator 1 PFIZER INC. $14,628.41 01/25/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949831177
Principal investigator 1 PFIZER INC. $1,092.26 01/21/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949828751
Principal investigator 1 GlaxoSmithKline, LLC. $591.31 01/14/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933021
Principal investigator 1 PFIZER INC. $7,300.80 01/11/2022 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949830517
Principal investigator 1 GlaxoSmithKline, LLC. $25,858.70 01/05/2022 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLL
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943933017